drugset / Trial / NCT00304499

Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence

NCT00304499

Phase 3 Completed 176 enrolled Alza Corporation
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the side-effect profile and efficacy of sustained release, OROS® and TTS, dosage forms of oxybutynin with immediate release (IR) oral oxybutynin and with placebo.

Timeline

Start
1995-12
Primary completion
Completion
1996-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxybutynin Small molecule 1.7 mg Oral
Subject Oxybutynin Small molecule 2.5 mg Oral

Indications

No indication recorded.